Aura Biosciences’ (AURA) Buy Rating Reaffirmed at HC Wainwright

Aura Biosciences (NASDAQ:AURA)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 210.73% from the stock’s current price.

Separately, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Aura Biosciences presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Price Performance

Shares of NASDAQ:AURA opened at $7.08 on Monday. The company has a market capitalization of $353.65 million, a PE ratio of -4.09 and a beta of 0.30. The business has a fifty day moving average price of $7.64 and a 200-day moving average price of $8.66. Aura Biosciences has a 1-year low of $6.33 and a 1-year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). On average, sell-side analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 23,045 shares of company stock worth $177,242. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in AURA. Long Focus Capital Management LLC raised its stake in Aura Biosciences by 123.9% during the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after buying an additional 1,404,228 shares during the last quarter. Levin Capital Strategies L.P. grew its holdings in shares of Aura Biosciences by 169.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after acquiring an additional 783,984 shares during the period. B Group Inc. purchased a new stake in Aura Biosciences during the fourth quarter valued at $3,885,000. Franklin Resources Inc. lifted its holdings in Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after acquiring an additional 215,597 shares during the period. Finally, Ensign Peak Advisors Inc boosted its position in Aura Biosciences by 43.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock worth $3,212,000 after purchasing an additional 118,000 shares during the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.